Respiratory Viruses & Breast Cancer Risk
Landmark Research Links COVID-19 to Increased cancer Mortality and Metastasis
New research published in Nature suggests that common respiratory viral infections, including COVID-19, may significantly increase the risk of cancer-related mortality and metastatic progression in cancer survivors. The findings, stemming from two large population studies, raise critical questions about the long-term impact of viral infections on individuals wiht a history of cancer, especially in the pre-vaccine era.
COVID-19 Infection doubles Cancer Mortality Risk in Survivors
A thorough study involving over 500,000 participants, conducted by researchers from Utrecht University and Imperial College London, investigated the link between COVID-19 infection and cancer-related mortality. The study focused on cancer survivors diagnosed at least five years before the pandemic, a group presumed to be in remission.
Among these survivors, 487 individuals who tested positive for COVID-19 were compared to 4,350 matched controls who tested negative. After excluding participants who died directly from COVID-19, the analysis revealed a striking finding: cancer patients who contracted COVID-19 faced nearly double the risk of dying from their cancer compared to those who remained COVID-19 negative.
“The effect was most pronounced in the first year after infection,” stated Dr. Vermeulen, a lead researcher on the study. This rapid progression of cancer following infection mirrors observations in animal models, where dormant cancer cells showed quick expansion.
Increased Risk of Metastasis to the Lungs in Breast Cancer Patients
A second study, utilizing the U.S. Flatiron health database, examined female breast cancer patients across 280 U.S. cancer clinics. Drs. Junxiao Hu and Dexiang Gao analyzed the incidence of lung metastases in COVID-19-negative patients versus those who tested positive for the virus.
The study compared 36,216 COVID-19-negative patients with 532 COVID-19-positive patients. Over an approximate 52-month follow-up period, patients diagnosed with COVID-19 were found to be almost 50% more likely to experience metastatic progression to the lungs compared to breast cancer patients who did not contract COVID-19.
Implications for Cancer Survivors and Future Research
These findings underscore a potential vulnerability for cancer survivors following common respiratory viral infections. “Our findings suggest that cancer survivors may be at increased risk of metastatic relapse after common respiratory viral infections,” Dr. Vermeulen commented. He emphasized that the study’s focus was on the period before COVID-19 vaccines became widely available.
The research team is now focused on understanding the underlying biological mechanisms that drive this phenomenon. “By understanding underlying mechanisms, we will work hard to develop interventions that can limit the risk of metastatic progression in cancer survivors who experience respiratory viral infections,” said Dr. DeGregori.
Future research plans include extending these analyses to other cancer types and metastatic sites, utilizing both animal models and further clinical data mining. “Respiratory viral infections are forever a part of our lives, so we need to understand the longer-term consequences of these infections,” Dr. DeGregori added.
This groundbreaking research highlights the critical need for continued vigilance and proactive management strategies for cancer survivors, particularly in the context of ongoing viral threats.
Reference: Chia SB, Johnson BJ, Hu J, et al. Respiratory viral infections awaken metastatic breast cancer cells in lungs.Nature. 2025:1-11. doi: 10.1038/s41586-025-09332-0
This article has been republished from materials provided by CU Anschutz. Note: Material may have been edited for length and content. For further details, please contact the cited source.*